Oncternal Therapeutics Stock News

ONCT recently presented new and impressive results at the American Society of Hematology's annual conference. I review this new data in detail below.

Oncternal Therapeutics Inc (ONCT) shares closed 0.4% lower than its previous 52 week low, giving the company a market cap of $119M. The stock is currently down 50.8% year-to-date, down 47.1% over the past 12 months, and down 55.9% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 47.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 70.9% The company's stock price performance over the past 12 months lags the peer average by 50.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today ann

Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfol

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q3 2021 Results - Earnings Call Transcript

Why I Added Oncternal Therapeutics To My Watchlist

SAN DIEGO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2021 Results - Earnings Call Transcript

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -14.29% and -18.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock

Shares of Oncternal Therapeutics (NASDAQ:ONCT) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 52.94% over the past year to ($0.16), w

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today repor

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou